<DOC>
	<DOCNO>NCT02137993</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety A-prexa compare Zyprexa patient schizophrenia , schizophreniform disorder schizoaffective disorder .</brief_summary>
	<brief_title>Efficacy Safety A-prexa Compared Zyprexa Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>20 year 65 year Schizophrenia patient acute exacerbation Understand requirement study voluntarily consent participate study Patients another psychiatric disorder Patients unstable medical condition Patients clinically important abnormality liver function test ( ï¼ž2.5 fold upper normal limit ) , ECG vital sign screen visit Uncontrolled diabetic patient ( plasma glucose level 126 mg/dl fast condition ) Patients history allergic reaction olanzapine Patient clinical response take two different atypical antipsychotic 4 week . Patient take clozapine within 12 week screen visit</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>